24/7 Patient Assistance: 760-405-8205

Tina Wood, MD

Medical Oncologist

Write a review
Doctor's profile photo

Request a call back

Conditions Treated Laryngeal Cancer Lung Cancer Ovarian Cancer Pericardial Mesothelioma Peritoneal Mesothelioma Pleural Mesothelioma Testicular Mesothelioma

  • Bio & Insurance Information

    Dr. Tina Wood graduated the medical school from Wake Forest School of Medicine and completed both her residency and fellowship program at University of Alabama Medical Center. She is specialized and also board certified in Medical Oncology. Dr. Wood has been in practice for more than 11 years and is affiliated with USA Children's & Women's Hospital. During her career, she has also contributed to four publications of medical interest.

  • Education & Training


    Wake Forest School of Medicine

    Medical School


    University of Alabama Medical Center



    University of Alabama Medical Center


  • Board Certifications

    American Board of Internal Medicine - Oncology

  • Hospital & Practice

    UAB Hospital

    Languages: English/Spanish

    (205) 934-3411

    1802 6th Ave S

    Birmingham, Alabama 35233

    Read More

    USA Children's & Women's Hospital

    Languages: English/Spanish

    (251) 415-1000

    1700 Center St

    Mobile, Alabama 36604

    Read More
  • Publications & Memberships

    Dr. Tina Wood has contributed to 3 publications.

    Patterns of Failure for Lymph Node-Positive Resected Pancreatic Adenocarcinoma After Adjuvant Radiotherapy or Gemcitabine-based Chemotherapy Alone.

    McDonald, A. M.,Dulaney, C. R.,López-Araujo, J.,Posey, J. A.,Keene, K. S.,Christein, J. D.,Heslin, M. J.,Wood, T. E.,Jacob, R.; J Gastrointest Cancer. 2015 Mar 19.

    See more >>

    By the pricking of my thumbs, something wicked this way comes: sporadic cancers versus eponymous hereditary cancer predisposition syndromes.

    Vaklavas, C., Ross, J.R., Nabell, L.M., Forero, A., Heslin, M.J., Wood, T.E.; J Natl Compr Canc Netw. 2012 Jan.

    See more >>

    Gemcitabine Plus nab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial.

    Von Hoff, D.D., Ramanathan, R.K., Borad, M.J., Laheru, D.A., Smith, L.S., Wood, T.E., Korn, R.L., Desai, N., Trieu, V., Iglesias, J.L., Zhang, H., Soon-Shiong, P., Shi...; J Clin Oncol. 2011 Dec 1.

    See more >>